Compare Dyne Therapeutics Inc. Common Stock (DYN) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs ING Groep NV — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while ING Groep NV trades at $33.42 (market cap $94.92B). The key difference: ING Groep NV is far larger — about 33.2× Dyne Therapeutics Inc. Common Stock's market cap, and ING Groep NV pays a 3.93% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and ING Groep NV for 94 Days on average.
| DYN | ING | |
|---|---|---|
Market Cap | $2.86B | $94.92B |
Volume | 3,341,579 | 2,055,666 |
Sector | Health | Financials |
52-Week High | $26.78 | $37.27 |
52-Week Low | $14.60 | $23.66 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $2.18B | $237.77B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ING trades at $33.46, up 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue reached $22.90 billion in 2025, with a net income margin of 28.34%. Analyst sentiment is positive, with 11 buy ratings and no sell ratings among 17 analysts. Recent news highlights an upgraded ROE target above 16% for 2027 and strategic focus on organic growth.
The outlook for ING is cautiously optimistic, supported by earnings momentum and favorable analyst coverage. Key opportunities include revenue growth and profitability targets, while risks involve persistent negative operating cash flows and regulatory scrutiny, such as recent capital requirements in Australia. The stock's valuation metrics, including a P/E of 12.99, suggest reasonable pricing relative to earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
